Novo Nordisk recently presented its growth strategy at its Capital Markets Day, aiming to diversify beyond its successful Wegovy and Ozempic injections, which are set to face patent expirations in the early 2030s. However, investor reaction was negative, leading to a decline in Novo's stock, as the growth targets announced were seen as unambitious and lacking clarity on a turnaround plan.
Meanwhile, Eli Lilly is gaining market share, particularly in the obesity pill segment, with its new drug Foundayo capturing one-third of new GLP-1 pill patients. Lilly's CEO, Dave Ricks, noted that 70% of Medicare patients using GLP-1s are on Lilly's drugs, highlighting its dominance in the market.
Analysts suggest that Lilly's commercial advantages and a robust pipeline of next-generation obesity drugs, including retatrutide, position it well to maintain its leadership. In contrast, Novo is betting on a diverse pipeline of over five potential blockbuster drugs by 2030 to offset the revenue loss from Wegovy and Ozempic.
Despite this, investor confidence remains shaky, particularly regarding the efficacy of its upcoming CagriSema drug, which has previously underperformed in trials. Novo's future hinges on successfully launching new products to fill the revenue gap left by its current leading drugs as competition intensifies